LZAGF:OTO-Lonza Group AG (USD)

COMMON STOCK | Diagnostics & Research | OTC Pink

Last Closing

USD 546

Change

-11.72 (-2.10)%

Market Cap

USD 9.42B

Volume

63.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lonza Group Ltd is a supplier of preservatives and biocide blends. The Company's operating business segments are The Lonza Pharma&Biotech and The Lonza Specialty Ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-25 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
LZAGY Lonza Group AG

N/A

USD 42.40B
WUXIF WuXi AppTec Co. Ltd

N/A

USD 16.47B
BMXMF bioMérieux S.A

N/A

USD 12.58B
ERFSF Eurofins Scientific SE

N/A

USD 11.87B
SKHHY Sonic Healthcare Ltd ADR

N/A

USD 8.28B
SKHCF Sonic Healthcare Limited

N/A

USD 8.25B
HNGZY Hangzhou Tigermed Consulting C..

N/A

USD 5.92B
DSRLF DiaSorin S.p.A

N/A

USD 5.02B
VIMGF Vimian Group AB (publ)

N/A

USD 1.34B
MRCHF H.U. Group Holdings Inc

N/A

USD 0.87B

ETFs Containing LZAGF

S2USAH:SW 3.40 % 0.00 %

N/A

N/A
S2EUAH:SW 3.26 % 0.00 %

N/A

N/A
S2EUBH:SW 2.89 % 0.00 %

N/A

N/A
S2USBH:SW 2.89 % 0.00 %

N/A

N/A
HEWL 2.59 % 0.03 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.31% 79% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.31% 79% B- 83% B
Trailing 12 Months  
Capital Gain -11.84% 68% D+ 51% F
Dividend Return 0.61% 30% F 7% C-
Total Return -11.24% 68% D+ 49% F
Trailing 5 Years  
Capital Gain 80.20% 80% B- 86% B+
Dividend Return 3.25% 29% F 10% F
Total Return 83.45% 80% B- 85% B
Average Annual (5 Year Horizon)  
Capital Gain 15.44% 57% F 62% D
Dividend Return 15.92% 56% F 59% D-
Total Return 0.48% 21% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 37.36% 80% B- 61% D-
Risk Adjusted Return 42.63% 87% B+ 81% B-
Market Capitalization 9.42B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector